Aurinia Pharmaceuticals (AUPH) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Immunome (IMNM) over the past year, losing 6.3% versus a loss of 15.3%. Over five years, IMNM leads with a -7.5% price change compared with -24.0% for AUPH. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.85 billion), about 1.1 times the size.
Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | IMNM |
|---|---|---|
| Share price | $14.70 | $15.69 |
| Market cap | $1.97B | $1.85B |
| 1-day change | -1.28% | -5.54% |
| YTD return | -7.84% | -26.96% |
| 1-year return | -6.25% | -15.33% |
| 5-year return | -23.95% | -7.54% |
| P/E ratio (TTM) | 6.45 | — |
| Forward P/E | 12.67 | — |
| EPS (TTM) | $2.28 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | $6.94M |
| Revenue growth (YoY) | +20.38% | -23.23% |
| Net income (latest FY) | $287.20M | $-212.39M |
| Gross margin | 88.46% | — |
| Operating margin | 37.06% | -3228.83% |
| Net margin | 101.47% | -3059.99% |
| 52-week high | $19.25 | $30.06 |
| 52-week low | $13.52 | $15.55 |
| Distance from 52-week high | -23.64% | -47.80% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +25.85% | +123.90% |
| Average volume | 858.74K | 1.36M |
| Shares outstanding | 134.00M | 118.07M |
| Employees | 128 | 267 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Aurinia Pharmaceuticals grew revenue faster in its latest fiscal year (+20.38% vs -23.23%).
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees
AUPH vs IMNM FAQ
Which is bigger, Aurinia Pharmaceuticals or Immunome?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.85B for Immunome (IMNM).
Which stock has performed better over the past year, AUPH or IMNM?
AUPH returned -6.25% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.